Is biotech M&A about to be revived?

Biotechnology valuations slumped in 2022, but unlike their related technology brethren, valuations have remained depressed in each of the following years. However, there are signs of movement as pharmaceuticals M&A picks up.

The JP Morgan Healthcare Conference in San Francisco – the industry’s major annual showcase – highlighted that there might be a possible trough in valuations as companies stock up on non-obesity products while the costs are reasonable. The conference also showcased where companies see the final frontiers for treatments in different therapeutic areas.